AMGN Stock Price Today (September 2026) — Amgen Inc. Analysis & Key Metrics 2026-09-03
Amgen Inc. (AMGN) is trading at $444.12, up 0.29% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $357.03 (-19.6% upside).
- Volatility remains elevated (20.40% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.50% YoY) alongside significant competitive pressures.
AMGN Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Amgen Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $277.10B
P/E Ratio
Forward P/E: 17.62
Revenue Growth
Year over Year
Analyst Target
+-19.6% upside potential
Key Investor Questions About AMGN
What investors need to know before buying
Based on current market data, AMGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 69.55)
- Fundamentals say: Caution warranted (high leverage concerns)
AMGN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AMGN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $57.30B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AMGN stock traded between $269.77 and $447.03—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.40% annualized volatility and β=0.51, the stock exhibits low sensitivity to market moves—making AMGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves?
Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Rare-Disease Drug Tavneos Faces UK Withdrawal
CSL Vifor holds the U.K. authorization and is leading regulator talks
Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Explore More Analysis for AMGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Amgen Inc.
Amgen Inc. (AMGN) is currently trading at $444.12. The RSI (14-day) is at 69.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $357.03 implies 19.6% downside from current levels. Volatility is moderate at 20.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amgen Inc. (AMGN): The trailing P/E ratio is 27.60, which is in line with broader market averages. The forward P/E is 17.62, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.29, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 20.54. Price-to-Sales is 6.30. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering AMGN, the consensus price target is $357.03. This represents a 19.6% downside from the current price of $444.12. The range spans from a low target of $215.00 to a high target of $427.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Amgen Inc. (AMGN) pays a dividend with a current yield of approximately 2.27%. The annualized dividend rate is $9.80 per share. The payout ratio is 60.9%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-08-21T00:00:00.000Z.
Key risks for Amgen Inc. (AMGN) investors include: 1. Elevated debt levels (D/E ratio of 490.28) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amgen Inc.'s (AMGN) current debt and financial health profile: Total debt stands at $57.30B. The debt-to-equity ratio is 490.28, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.37, indicating adequate short-term liquidity. The quick ratio is 0.95. The company holds $13.99B in cash and equivalents. Free cash flow is positive at $8.65B, providing a cushion for debt servicing and shareholder returns.